Qsymia

Qsymia (phentermine/topiramate extended-release) is an oral, once-daily prescription combination capsule approved for chronic weight management in adults and adolescents 12 and older with obesity or with overweight and a weight-related condition. It pairs two well-known medications — phentermine, a short-term appetite suppressant, and topiramate, an antiepileptic that also reduces appetite — into a single capsule designed for long-term use alongside diet and exercise.

Qsymia belongs to the Weight Loss Medications class and was FDA-approved in 2012. Unlike short-term phentermine monotherapy, the combination is approved for chronic management. The phentermine component is a Schedule IV controlled substance, so Qsymia must be prescribed by a clinician and dispensed through certified pharmacies under the Qsymia REMS program because of fetal toxicity concerns with topiramate.

## What Qsymia is used for

Qsymia is prescribed for adults with a body mass index (BMI) of 30 or greater, or 27 or greater with a weight-related condition (such as type 2 diabetes, high blood pressure, or dyslipidemia). It is also approved for adolescents 12–17 with a BMI at or above the 95th percentile for age and sex. Qsymia is intended as an adjunct to a reduced-calorie diet and increased physical activity.

## Dosage and how to take Qsymia

Qsymia is taken once daily in the morning, with or without food, but avoid taking it in the evening due to insomnia risk. The typical titration is:

• Days 1–14: 3.75 mg / 23 mg once daily
• Day 15 onward: 7.5 mg / 46 mg once daily
• Evaluate at 12 weeks — if you have not lost at least 3% of your baseline weight, your prescriber may escalate to 11.25 mg / 69 mg for 14 days, then 15 mg / 92 mg once daily.
• Re-evaluate at 12 weeks on top dose — discontinue if ≥5% weight loss is not achieved.

Dose tapering is recommended when stopping the 15/92 mg strength to reduce seizure risk from abrupt topiramate withdrawal.

## Side effects of Qsymia

Common side effects include paresthesia (tingling in hands or feet), dizziness, altered taste (especially with carbonated drinks), insomnia, constipation, and dry mouth. Most common side effects diminish over the first weeks of treatment.

Serious side effects include fetal toxicity (oral cleft risk in early pregnancy), elevated heart rate, mood changes including suicidal ideation, acute angle-closure glaucoma, metabolic acidosis (low bicarbonate), cognitive impairment, and kidney stones. Severe rash and oligohidrosis (decreased sweating with risk of hyperthermia) are rare.

## Managing common side effects

• Paresthesia: usually self-limited; ensure adequate potassium intake.
• Insomnia: take Qsymia in the morning; avoid caffeine after noon.
• Dry mouth: sugar-free gum or lozenges; sip water frequently.
• Constipation: increase fiber and water; consider a stool softener.
• Altered taste of carbonated drinks: common with topiramate — typically resolves or is tolerated.

## Warnings and precautions

Qsymia is contraindicated in pregnancy because topiramate can cause oral clefts. A negative pregnancy test is required before starting and monthly thereafter, and effective contraception must be used. Topiramate may reduce the effectiveness of estrogen-containing oral contraceptives, so a non-hormonal backup method is often recommended. Avoid in patients with glaucoma or hyperthyroidism. Use caution with cardiovascular disease, kidney impairment, or hepatic impairment.

## Qsymia and weight loss results

Clinical trials reported average weight loss of approximately 8–10% of body weight at the 7.5/46 mg dose and 10–12% at the top 15/92 mg dose over 1 year, compared to ~1.5% with placebo. One-month Qsymia results often show 3–5 lb of early loss, accelerating over the first 12 weeks.

## Qsymia vs Contrave, Wegovy, and Phentermine

• Qsymia vs Contrave: Both are oral combination drugs. Contrave (naltrexone/bupropion) tends to produce slightly less weight loss but avoids controlled-substance status and topiramate's fetal risk.
• Qsymia vs Wegovy / Zepbound: GLP-1 / GIP-GLP-1 injectables produce greater average weight loss (15–20%+), but are injections and far more expensive. Qsymia is a less costly oral option.
• Qsymia vs Phentermine: Phentermine alone is approved only short-term (≤12 weeks); Qsymia is approved for chronic use because the topiramate component permits long-term combination therapy.

## Cost, savings card, and getting Qsymia

Without insurance, Qsymia typically runs $200–$250 per month. The Qsymia Advantage savings card can reduce the cost for commercially insured patients to as little as $98/month, and the manufacturer offers a Home Delivery Pharmacy through Qsymia.com. GoodRx coupons may help cash-pay patients at participating pharmacies. Search for Qsymia manufacturer coupon, Qsymia discount card, or Qsymia cost with insurance to find current programs.

## How to get Qsymia online

Qsymia is available via telehealth platforms that include licensed prescribers; the medication itself must come from a Qsymia REMS-certified pharmacy. Online doctors who prescribe Qsymia typically evaluate BMI, comorbidities, blood pressure, and any contraindications before prescribing.

## Drug interactions

MAOIs are contraindicated with phentermine due to hypertensive crisis risk — wait 14 days after stopping an MAOI. Topiramate reduces oral contraceptive efficacy — plan for backup contraception. Combine with caution with CNS depressants, other carbonic anhydrase inhibitors (zonisamide, acetazolamide), and any drug that lowers seizure threshold.

## Monitoring and lifestyle

Monthly pregnancy tests are required throughout treatment in women of reproductive potential. Periodic monitoring includes heart rate, blood pressure, serum bicarbonate (for metabolic acidosis), serum creatinine, and mood assessment. Adequate hydration helps reduce kidney stone risk. Avoid alcohol and limit caffeine.

## Stopping Qsymia

Do not stop the 15/92 mg dose abruptly — taper by reducing to one dose every other day for at least one week to lower seizure risk from topiramate withdrawal. After discontinuation, weight regain is common without sustained lifestyle changes or transition to another agent.

## Use in specific populations

Pregnancy: Contraindicated. Breastfeeding: Not recommended. Children: Approved for ages 12–17 at standard adult titration. Older adults: Use with caution; renal function may be reduced.

## Storage

Store at room temperature (20–25°C / 68–77°F) in the original container with the Medication Guide. Keep out of reach of children.

## Key takeaways

• Qsymia is an oral once-daily phentermine/topiramate combination approved for chronic weight management.
• Average weight loss is 8–12% over 1 year, varying with dose.
• Schedule IV controlled substance and REMS-restricted due to topiramate fetal toxicity.
• Monthly pregnancy testing and effective contraception are required for women of reproductive potential.
• Qsymia Advantage savings card and certified-pharmacy home delivery can reduce out-of-pocket cost.

## Medical disclaimer

This article about Qsymia (phentermine/topiramate) is for general education and is not a substitute for professional medical advice, diagnosis, or treatment. Always follow the guidance of your physician or pharmacist and the instructions on your prescription label.